Roth Capital Downgrades Alexza Pharmaceuticals To Neutral

Roth Capital downgraded Alexza Pharmaceuticals ALXA from Buy to Neutral. The target price for Alexza Pharmaceuticals has been lowered from $10.00 to $5.50. Alexza Pharmaceuticals shares have declined 6.54% over the past 52 weeks, while the S&P 500 index has gained 12.49% in the same period. Alexza Pharmaceuticals' shares gained 2.97% to close at $4.86 yesterday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: DowngradesAnalyst RatingsRoth Capital
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!